Wasatch Advisors LP Has $7.77 Million Stake in biote Corp. (NASDAQ:BTMD)

Wasatch Advisors LP lifted its holdings in shares of biote Corp. (NASDAQ:BTMD) by 8.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,809 shares of the company’s stock after buying an additional 107,792 shares during the quarter. Wasatch Advisors LP owned about 2.57% of biote worth $7,772,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in biote by 1,016.6% during the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after purchasing an additional 600,956 shares during the period. Renaissance Technologies LLC grew its holdings in biote by 251.8% during the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after purchasing an additional 138,200 shares during the period. Sanders Morris Harris LLC grew its holdings in biote by 131.2% during the third quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company’s stock valued at $1,010,000 after purchasing an additional 102,706 shares during the period. Skylands Capital LLC grew its holdings in biote by 36.2% during the second quarter. Skylands Capital LLC now owns 160,845 shares of the company’s stock valued at $1,202,000 after purchasing an additional 42,729 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in biote by 59.0% during the second quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after purchasing an additional 34,999 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Stock Performance

Shares of NASDAQ BTMD opened at $6.61 on Friday. The stock has a market cap of $359.19 million, a P/E ratio of 25.42 and a beta of 0.94. The firm has a 50 day moving average price of $5.59 and a 200 day moving average price of $6.31. biote Corp. has a 52-week low of $3.65 and a 52-week high of $8.44.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.